BCMA CART

DRUG2 trials

Conditions

Cytogenetics Ultra High RiskEarly ProgressionLight Chain AmyloidosisNon Paraosseous Extramedullary InfiltrationPlasma Cell LeukemiaPrimary RefractoryR2-ISS-IV /MPSS-IVUltra High Risk mm (uhr-mm), 18-70 Years Old, Suitable for ASCT. And Meet Any of the Following uhr-mm Definitions

Phase 1

Autologous Transplantation Combined With BCMA CAR-T in the Treatment of UHR-MM

RecruitingNCT07109323

Institute of Hematology & Blood Diseases Hospital, ChinaCytogenetics Ultra High Risk, Early Progression, Non Paraosseous Extramedullary Infiltration +4

Start: 2025-03-03End: 2030-03-02Target: 50Updated: 2025-08-07

Unknown Phase

Exploratory Clinical Study on the Safety and Efficacy of Targeted BCMA Autologous CART Cell Injection in Subjects With Recurrent/Refractory Light Chain Amyloidosis

RecruitingNCT06983951

Beijing Boren HospitalLight Chain Amyloidosis

Start: 2025-02-20End: 2027-09-30Target: 30Updated: 2025-05-21

BCMA CART

Sponsors

Conditions

Phase 1

Unknown Phase